Publications

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy. American Society of Clinical Oncology Annual Meeting (June 2-6, 2023)
Maslak PG, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2:224-34.{" "} https://doi.org/10.1182/bloodadvances.2017014175
Zauderer MG, et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin Cancer Res. 2017;23:7483-9; doi:{" "} https://doi.org/10.1158/1078-0432.ccr-17-2169{" "}
Brayer J, et al. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015;90:602-7; doi:{" "} https://doi.org/10.1002/ajh.24014
Maslak PG, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116:171-9; doi:{" "} https://doi.org/10.1182/blood-2009-10-250993 {" "}
Krug LM, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 2010;59: 1467-79; doi:{" "} https://doi.org/10.1007/s00262-010-0871-8 {" "}
May RJ, et al. Peptide epitopes from the Wilms’ tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13:4547-55; doi:{" "} https://doi.org/10.1158/1078-0432.ccr-07-0708 {" "}
Pinilla-Ibarz J, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia. 2006;20:2025-33; doi:{" "} https://doi.org/10.1038/sj.leu.2404380 {" "}

WT1 Antigen ranked by National Cancer Institute as a top priority for immunotherapy

Galinpepimut-S (GPS)

Publications